ISB 1342, Ichnos’ CD38 x CD3 T-cell engager for relapsed/refractory multiple myeloma, is highlighted on the cover of the American Society of Hematology's journal, Blood. In this latest print edition of the journal, you’ll find our latest research article, Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma: https://lnkd.in/ezwyFBUE
They are reporting preclinical data. They still don’t have clinical data?
Last month, our team proudly wore red to show our deep commitment to finding new treatments for blood cancers. #BloodCancerAwarenessMonth #BloodCancer #CancerResearch
We are pleased to announce a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of The National Institutes of Health (U.S.). Under the CRADA, IGI and NCI will collaborate on evaluating IGI's proprietary Cbl/b small molecule, GRC 65327, in Triple Negative Breast Cancer (TNBC). NCI's Stanley Lipkowitz, MD, PhD, will build on his early research on Cbl/b’s role as a negative regulator of the adaptive immune system. His lab's work in late-stage TNBC complements IGI's program to advance GRC 65327 in other solid tumors. Read more: https://bit.ly/4dr8qJq #ClinicalResearch #Innovation #Oncology #BreastCancer
👟 Join us to accelerate a cure for multiple myeloma at the Multiple Myeloma Research Foundation - MMRF’s Walk/Run in NYC or virtually. More here: https://lnkd.in/gtUCHPX2 #MMRF
September reminds us of our deep commitment to battling blood cancers — a cause that resonates profoundly with us at Ichnos Glenmark Innovation and Glenmark Pharmaceuticals. It’s a month dedicated to raising awareness about blood cancers, and I am proud to share our commitment to this cause through our participation in the MMRF Walk for Multiple Myeloma. Blood Cancer Awareness Month is not just a time to reflect, but an opportunity to act and make a difference. On October 5th, we will be walking in New York City, and we invite all of you to join us in this vital effort. If you’re not in New York, you can still participate virtually from October 5th to October 11th. Your involvement will directly impact the fight against multiple myeloma and help us move closer to a cure. Let’s come together, make every step count, and show our unwavering commitment to this important cause. Join us or donate at: https://lnkd.in/g4bUZTjT
Today we celebrate #WorldCancerResearchDay. We’re proud to be cancer researchers working toward a world in which there are cures for all cancers. #CancerResearch #Cancer
September turns red each year for Blood Cancer Awareness Month. Blood cancers – which include leukemia, lymphoma, and multiple myeloma – are some of the world’s most prevalent and dangerous types of cancer. At IGI, we’re focused on advancing our two clinical programs for the potential treatment of multiple myeloma. Find out more: https://bit.ly/3B9KwVs #Hematology #Cancer #Oncology #ThisIsBloodCancer
Check out this Fierce Biotech article by Darren Incorvaia on our trispecific antibody for multiple myeloma and preclinical findings published in Nature Cancer. Cyril Konto, M.D., President, Executive Director & CEO, discusses how ISB 2001 works and demonstrates the value of the BEAT platform. Article here: https://bit.ly/4gwXyMT #biotechnology #drugdiscovery #oncology
OPEN POSITIONS AT IGI – NYC - Clinical Scientist, Associate Director - Data Management, Associate Director - Program Development Team Lead, Sr / Exec Director - Clinical Trial Management, Director All roles are - Exempt; not eligible for overtime. - Hybrid schedule (3 days in the NYC office) No relocation or immigration sponsorship is being offered at this time. Candidate must be located within the tri-state area (NY, NJ, CT). PLEASE REACH OUT TO THE IGI HR US TEAM VIA EMAIL ASKHRUS@IGINNOVATE.COM Ichnos Sciences, Inc. & Ichnos Glenmark Innovation are equal opportunity employers, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, sexual orientation, gender identity, disability status, height, weight, protected veteran status, or any other characteristic protected by law.
We’re thrilled to announce our research publication in Nature Cancer on ISB 2001, IGI’s innovative BCMA x CD38 x CD3 trispecific T-cell engager for refractory/relapsed multiple myeloma. The publication highlights preclinical findings demonstrating that ISB 2001 can potentially overcome myeloma cell escape mechanisms. The data show superior killing potency of multiple myeloma tumor cells by ISB 2001 when compared to several bispecific therapies and combination of therapies. IGI plans to release the preliminary clinical results of the ongoing Phase 1 dose-escalation study at an upcoming conference. The article is available at https://lnkd.in/e4tKsEc3 #CancerResearch #Cancer #Myeloma Nature Portfolio
What exactly are multispecific antibodies – or multispecifics™? Learn more about the advantages of multispecifics at https://bit.ly/3SHzDAh #biotechnology #biologics #antibodies #partnering #biopharma
Highlights of our most recent quarter include an oral presentation on our novel, clinical-stage multispecific™ asset ISB 2001 at AACR in April 2024. Read more about how we continue to advance our innovations in oncology in our quarterly update: https://bit.ly/3YIa0D3 #Biotechnology #CancerResearch #AACR2024
Congratulation! And a big shout out to the discovery teams at Biopôle!